Peresolimab humanized IgG1 mab
➢ stimulates PD-1 & physiological immune inhibitory pathways
➢ In RA phase 2 study, superior to placebo at Week 12 DAS28/CDAI
➢ safety events were similar between treatment groups
Emery P #L03 https://t.co/4Jd79CW5RA #ACR22 #ACRBest @RheumNow https://t.co/PSuLQgjYuz
Links:
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis - ACR Meeti…
http://bit.ly/3tt5EPn
14-11-2022